UNIVERSITY^{OF} BIRMINGHAM University of Birmingham Research at Birmingham

The potential interaction between medical treatment and radioiodine treatment success: A systematic review.

Zannat, Riazul; Lee, Jonathan; Muzaffar, Jameel; Read, Martin; Brookes, Kate; Sharma, Neil; Boelaert, Kristien; McCabe, Christopher; Nieto, Hannah

DOI: 10.3389/fendo.2022.1061555

License: Creative Commons: Attribution (CC BY)

Document Version Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Zannat, R, Lee, J, Muzaffar, J, Read, M, Brookes, K, Sharma, N, Boelaert, K, McCabe, C & Nieto, H 2023, 'The potential interaction between medical treatment and radioiodine treatment success: A systematic review.', *Frontiers in Endocrinology*, vol. 13, 1061555. https://doi.org/10.3389/fendo.2022.1061555

Link to publication on Research at Birmingham portal

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



OPEN ACCESS

EDITED BY Trevor Edmund Angell, University of Southern California, United States

REVIEWED BY Antonio Matrone, University of Pisa, Italy Eyal Robenshtok, Rabin Medical Center Israel

*CORRESPONDENCE Hannah R. Nieto ⋈ h.dixon@bham.ac.uk Christopher J. McCabe ⋈ C.J.MCCABE.MED@bham.ac.uk

[†]These authors share senior authorship

SPECIALTY SECTION

This article was submitted to Thyroid Endocrinology, a section of the journal Frontiers in Endocrinology

RECEIVED 04 October 2022 ACCEPTED 06 December 2022 PUBLISHED 04 January 2023

CITATION

Zannat R, Lee J, Muzaffar J, Read ML, Brookes K, Sharma N, Boelaert K, McCabe CJ and Nieto HR (2023) The potential interaction between medical treatment and radioiodine treatment success: A systematic review. *Front. Endocrinol.* 13:1061555. doi: 10.3389/fendo.2022.1061555

COPYRIGHT

© 2023 Zannat, Lee, Muzaffar, Read, Brookes, Sharma, Boelaert, McCabe and Nieto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or

reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The potential interaction between medical treatment and radioiodine treatment success: A systematic review

Riazul Zannat¹, Jonathan Lee², Jameel Muzaffar³, Martin L. Read¹, Katie Brookes¹, Neil Sharma^{4,5}, Kristien Boelaert⁶, Christopher J. McCabe^{1,7*†} and Hannah R. Nieto^{1*†}

¹Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom, ²Department of Ear, Nose and Throat Surgery, Warwick Hospital, University Hospitals of South Warwickshire NHS Foundation Trust, Birmingham, United Kingdom, ³Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom, ⁴Department of Ear, Nose and Throat Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁵Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom, ⁶Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, ⁷Birmingham Health Partners, University of Birmingham, Birmingham, United Kingdom

Introduction: Radioactive iodine (RAI) therapy is a critical component in the post-surgical management of thyroid cancer patients, as well as being a central therapeutic option in the treatment of hyperthyroidism. Previous work suggests that antithyroid drugs hinder the efficacy of RAI therapy in patients. However, the effects of other background medications on RAI treatment efficacy have not been evaluated. Therefore, we performed a systematic review and meta-analysis investigating the potential off-target effects of medication on RAI therapy in patients with thyroid cancer and hyperthyroidism.

Methods: Systematic review and meta-analysis according to the 2020 PRISMA guidelines. Databases searched: MEDLINE, EMBASE and Cochrane Library for studies published between 2001 and 2021.

Results: Sixty-nine unique studies were identified. After screening, 17 studies with 3313 participants were included. One study investigated thyroid cancer, with the rest targeted to hyperthyroidism. The majority of studies evaluated the effects of antithyroid drugs; the other drugs studied included lithium, prednisone and glycididazole sodium. Antithyroid drugs were associated with negative impacts on post-RAI outcomes (n = 5 studies, RR = 0.81, p = 0.02). However, meta-analysis found moderate heterogeneity between studies (I2 = 51%, τ 2 = 0.0199, p = 0.08). Interestingly, lithium (n = 3 studies), prednisone (n = 1 study) and glycididazole (n = 1 study) appeared to have positive impacts on post-RAI outcomes upon qualitative analysis.

Conclusion: Our systematic review strengthens previous work on antithyroid medication effects on RAI, and highlights that this field remains under researched especially for background medications unrelated to thyroid disease, with very few papers on non-thyroid medications published.

Systematic review registration: https://www.crd.york.ac.uk/prospero/ display_record.php, identifier CRD42021274026.

KEYWORDS

radioiodine, thyroid cancer, hyperthyroidism, prednisone, glycididazole sodium, lithium, carbimazole, antithyroid drugs

Introduction

Rationale

 β -emitting radioiodide (¹³¹I) has been utilized for over 75 years to safely and efficiently destroy remaining thyroid cancer cells post-surgery, and to ablate thyroid cells in patients with hyperthyroidism (1). The sodium iodide symporter (NIS) is the sole known transporter of iodide into human cells (2). Different patient and disease characteristics influence treatment course and outcome, but a fuller understanding of the factors which impact treatment success might facilitate enhanced outcomes in the management of both thyroid tumors and hyperthyroidism.

The ability of NIS to uptake radioiodide is diminished in 25-50% of thyroid cancer patients, due to reduced expression and mislocalization away from the plasma membrane (PM) (3, 4), its only site of transport activity. The regulation of NIS expression and function is complex, being governed *via* transcription factors, miRNAs, promoter methylation and histone acetylation, hormonal signaling, post-translational modification, and by iodide itself (5–10). Pioneering recent studies in differentiated thyroid cancer have shown that treatment with MEK and/or BRAF inhibitors – as well as other pathway targeted approaches - increases ¹³¹I avidity in subsets of patients, raising the possibility of achieving a tumor response following ¹³¹I treatment (11–14). However, what is much less well understood is the impact of contemporaneous therapies at the time of treatment on clinical success and outcome.

Clinical predictors of 131I therapy failure in differentiated thyroid cancer may include tumor focality and lymph node invasion at surgical resection (15), although predictors of treatment success in hyperthyroidism are less clear. Walter et al. (16) first highlighted the counterproductive effect of antithyroid drugs on radioactive iodine treatment. In particular, drugs such as carbimazole and propylthiouracil (PTU) had a negative influence on RAI uptake when taken in the week prior to RAI therapy or post-RAI therapy (16). These findings suggest that antithyroid drugs may have influenced RAI kinetics, possibly mediated by a reduction in free radicals (16). Further studies are needed to investigate whether the efficacy of RAI therapy is similarly diminished by off-target effects arising from other coincident medications.

More widely, it has been documented that exposure to background pollutants can significantly modulate thyroid function and treatment. Phthalate exposure in pregnancy (17), for example, has been shown to modulate thyroid function, and perchlorate, a competitive inhibitor of NIS, is detrimental to radioactive iodine treatment (18, 19). As such, patients' medication (administered for other conditions) might potentially interact with the cellular mechanisms which mediate radioactive iodine uptake, critically affecting outcomes in both hyperthyroidism treatment and thyroid cancer ablation therapy. Our study therefore seeks to better understand possible interactions of common medications on the efficacy of radioactive iodine administration.

Objectives and research question

The aim of this systematic review is to evaluate whether medications taken by patients with thyroid cancer or hyperthyroidism receiving RAI significantly impact RAI treatment success (i.e. response rate for thyroid cancer or if patients were rendered euthyroid or hypothyroid for hyperthyroidism). This review was prospectively registered on PROSPERO to minimize bias and prevent duplication and was designed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (20).

Methods

Search strategy and data sources

The search strategy was developed in conjunction with an information specialist librarian (Evidence search: 'Do commonly used drugs diminish the efficacy of radioiodine treatment in hyperthyroidism and thyroid cancer?' performed by Jennifer Manders on 18th August, 2021. BIRMINGHAM, UK: University Hospitals Birmingham (UHB) Library and Knowledge Service). Records published between 2001 and 2021 were collected by searching systematically on Medline, EMBASE and the Cochrane Library. Examples of search terms used can be seen in Table 1 of the current paper and Table 1 of the Supplementary Material. Studies were performed on adult patients only and no other limitations were applied to the search. Following this, 67 duplicated results were removed. Five papers were identified for eligibility screening through citation searching.

Study selection and data extraction

Records were screened for inclusion according to the inclusion and exclusion criteria summarized in Table 2. Randomized-control trials (RCTs), case-control studies or cohort studies that studied the effect of medication on radioactive iodine treatment prognosis in human patients with thyroid cancer or hyperthyroidism were included, whilst systematic reviews and laboratory investigations were excluded.

Initially, the 69 studies gathered from the search were screened by title and abstract by two independent reviewers [RZ and JL]. Disagreements were resolved by discussion and a third reviewer [HN]. Following the initial screening, the full-text articles of 49 studies were obtained for a full-text screening against the aforementioned inclusion criteria. The reference lists of these papers were searched, resulting in the screening of an additional five articles. In total, 17 articles were included for data extraction.

Data were extracted and recorded in a standard Excel spreadsheet by one reviewer [RZ] and checked by a separate reviewer [JL]. Patient characteristics, study characteristics and patient outcomes were recorded.

Quality assessment

To assess the risk of bias of the randomized-control trials, the Cochrane risk-of-bias tool for randomized trials (RoB 2) was used (22). This tool allowed for the appraisal of the randomization process, deviations, measurement and reporting of outcomes of each randomized control trial. To assess the risk of bias of the case-control studies and cohort studies, the Critical Appraisal Skills Programme (CASP) checklists for case-control studies and cohort studies were used (23, 24). These checklists evaluate the validity of the study, the method, the results and their relevance for our study population.

Data synthesis and analysis

A meta-analysis was performed examining cure rates after radioactive iodine for patients on carbimazole or methimazole vs

control (R version 4.1.2, metabin package). This was conducted as a random effects meta-analysis, with study heterogeneity examined using the I² statistic. This was considered low at < 50%, moderate at 50 to 75% and high at >75%. The weight to each study, relative risk (RR) and 95% confidence intervals were calculated and τ^2 using the Paule-Mandel estimator. A subset analysis of randomized vs non-randomized studies was also performed.

Results

Description of studies

The initial search found 136 studies from which 67 duplicate studies were removed. Following this, 69 studies were screened by title and abstract against the inclusion and exclusion criteria (Table 2) and 20 studies were excluded. Seven papers could not be retrieved for full-text screening. Forty-two studies were subject to full-text screening and a further 27 were excluded (Figure 1). An additional five studies were found by citation searching and two of these were eligible for full-text screening. Figure 1 shows the PRISMA flow diagram of the selection process.

A total of 17 studies were included in this systematic review with 3313 patients. Of the 17 included studies, nine were RCTs, seven were cohort studies and one was a case-control study. All studies investigated outcomes in patients with hyperthyroidism with the exception of Wen et al. (25) who investigated outcomes in patients with thyroid cancer.

In every study there were more female participants than male participants, with mean ages ranging from 36.2 years to 65.3 years. Most studies investigated the effect of antithyroid drugs, such as methimazole, thiamazole, carbimazole and propylthiouracil (26–37) on RAI outcomes. Three studies researched lithium (38–40), one study researched lithium carbonate and prednisone in addition to thiamazole (34), and one study researched glycididazole sodium (25).

Thyroid status was defined as euthyroid, hypothyroid or hyperthyroid and was measured using standard diagnostic assays. Six studies (27, 29, 30, 34, 35, 40) evaluated thyroid status using free triiodothyronine (FT3), free thyroxine (FT4) and thyroid stimulating hormone (TSH) concentrations. Studies used differing thyroid blood assays and the need for repeat RAI doses to assess thyroid status (26, 28, 31, 32, 36, 37). The outcomes for patients with thyroid cancer were measured by evaluating unstimulated thyroglobulin (Tg) levels and ¹³¹I whole body scanning at 12 and 24 weeks following RAI administration in the study by Wen et al. (25). Four studies (33, 38, 39, 41) did not provide details of how thyroid status was assessed. A summary of study characteristics is provided in Table 3.

In most of the studies of patients with hyperthyroidism (26– 40), success of RAI treatment was defined as either euthyroidism TABLE 1 Search strategy on MEDLINE for records published between 2001 and 2021.

Search term	Result
1. (hyperthyroidism).ti,ab	20752
2. ("overactive thyroid").ti,ab	21
3. (Thyroid ADJ1 (Cancer OR neoplasms)).ti,ab	25726
4. ("papillary carcinoma").ti,ab	5725
5. ("follicular carcinoma").ti,ab	2018
6. ((Medullary OR anaplastic) ADJ1 "thyroid carcinoma").ti,ab	5304
7. (1 OR 2 OR 3 OR 4 OR 5 OR 6)	55365
8. ("radioactive iodine").ti,ab	5862
9. (Radioiodine).ti,ab	9215
10. (I-131).ti,ab	4315
11. (8 OR 9 OR 10)	17905
12. (Amiodarone).ti,ab	9690
13. (Alendronate).ti,ab	4812
14. (Clindamycin).ti,ab	11112
15. (Escitalopram).ti,ab	2710
16. (Mebeverine).ti,ab	165
17. ("Enalapril maleate").ti,ab	397
18. (Diltiazem).ti,ab	8680
19. (Amitriptyline).ti,ab	158
20. (Exemestane).ti,ab	1368
21. (Raloxifene).ti,ab	3369
22. (Spironolactone).ti,ab	6040
23. (Alfacalcidol).ti,ab	645
24. (Digoxin).ti,ab	11770
25. (Celecoxib).ti,ab	6552
26. ("Cyproterone acetate").ti,ab	2503
27. (12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26)	68097
28. (Medication).ti,ab	231230
29. (Medicine).ti,ab	488876
30. (Drug).ti,ab	1227922
31. (27 OR 28 OR 29 OR 30)	1908684
32. (7 AND 11 AND 31)	828
33. 32 [DT 2001-2021]	454
In addition to using generic search terms to capture all medications, specific drugs from a previous screening study (21) were included in the search. ti, title; ab, abstrac	t.

Inclusion criteria	Exclusion criteria
Adults with hyperthyroidism or thyroid cancer	Children, animals
Randomised control trials, case-control studies, cohort studies	Review, systematic review, laboratory research
Medication having an effect on RAI treatment	Non-English language

or hypothyroidism. In the one study of patients with thyroid cancer (25), RAI treatment success was defined as the absence of thyroid bed uptake 131 I and Tg concentrations below 10 μ g/ml with no serum Tg antibodies.

Quality of studies

The majority of the studies were prospective, with three being retrospective. The study sample sizes were generally small, and ranged from 53 to 707 patients in the final analysis.

A summary of the Cochrane risk of bias assessment is provided in Table 4. The overall quality of the nine RCTs (25– 29, 36, 38, 39, 41) was poor with five reaching high concern and three with some concerns. Six studies were assessed to be of some concern in domain 1 due to lack of information regarding concealment of randomization (Table 4). All studies except for two (29, 38) were assessed to be of high or some concern in regards to domain 2 due to the lack of mention of placebo use in the control groups or uneven or large losses to follow-up that were not accounted for in the analysis. Six of the nine studies were assessed to be of low concern in domain 3, the three studies that were of high concern or some concern had missing outcome data. Two studies showed differences in the measurement of outcomes between intervention and control groups, thus were assessed as being of high concern in domain 4. Four studies were assessed to be of high concern in domain 5 due to the absence of post-RAI outcome results or because the method of outcome measurement i.e. thyroid status post-RAI was not mentioned as part of the method.

Table 5 is a summary of the quality assessment of the cohort studies using the CASP checklist. All seven cohort studies (30–33, 35, 37, 40) scored well for questions 1, 4, 7, 8 and 9, thus displaying focus and sufficient measurement of outcomes and appropriate follow-up (Table 5). All studies were judged to have recruited the cohorts in an acceptable way except for one (31), due to the uneven group sizes and other significant differences in baseline characteristics. The measurement of exposure was deemed unclear in three studies. Walter et al. (37) failed to mention confounding factors in their study and Karyampudi et al. (35) were unable to take into account confounding factors as their small sample



TABLE 3 Study characteristics.

Author	Year	Country	Number of patients	Indication for RAI	Study design	Medication	Comparator	RAI dose
Andrade et al. (26)	2001	Brazil	61	Hyperthyroidism	RCT	Methimazole	No methimazole	Uptake- adapted
Bal et al. (38)	2002	India	316	Hyperthyroidism	RCT	Lithium	No lithium	218- 433 MBq
Bogazzi et al. (39)	2002	Italy	36	Hyperthyroidism	RCT	Lithium	No lithium and different durations and starting points for lithium treatment	479- 550 MBq
Bogazzi et al. (40)	2010	Italy	647	Hyperthyroidism	Cohort	Lithium	No lithium	Uptake- adapted
Bonnema et al. (27)	2006	Denmark	75	Hyperthyroidism	RCT	Methimazole	Discontinuation of methimazole 8 days before RAI therapy	Uptake- adapted
Bonnema et al. (28)	2011	Denmark	100	Hyperthyroidism	RCT	Methimazole +levothyroxine	Discontinuation of methimazole 8 days before RAI therapy	Uptake- adapted
Braga et al. (29)	2002	America	34	Hyperthyroidism	RCT	Methimazole	No drug	Uptake- adapted
Eschmann et al. (30)	2006	Germany	141	Hyperthyroidism	Cohort	Carbimazole, methimazole, propylthiouracil	Continuation of ATD after RAI therapy	Uptake- adapted
Karyampudi et al. (35)	2014	India	70	Hyperthyroidism	Cohort	Carbimazole	No ATD	5 mCi
Körber et al. (<mark>31</mark>)	2001	Germany	707	Hyperthyroidism	Cohort	Carbimazole, methimazole	Discontinuation of ATD at least 14 days before RAI	Uptake- adapted
Oszukowska et al. (34)	2010	Poland	200	Hyperthyroidism	Case- control	Thiamazole, lithium carbonate, prednisone	Drugs compared, no placebo	Uptake- adapted
Płazińska et al. (41)	2011	Poland	256	Hyperthyroidism	RCT	Lithium carbonate	No lithium	Uptake- adapted
Santos et al. (32)	2004	Brazil	100	Hyperthyroidism	Cohort	Propylthiouracil, methimazole	No drug	10 mCi
Walter et al. (36)	2006	Switzerland	207	Hyperthyroidism	RCT	Carbimazole	No carbimazole or carbimazole discontinuation 3 days prior to RAI therapy	Uptake- adapted
Walter et al. (37)	2009	Switzerland	228	Hyperthyroidism	Cohort	Carbimazole	No carbimazole	Uptake- adapted
Wen et al. (25)	2015	China	53	Thyroid cancer	RCT	Glycididazole sodium	Saline (monotherapy)	4.44 GBq
Zantut- Wittman et al. (33)	2005	Brazil	82	Hyperthyroidism	Cohort	Methimazole, propylthiouracil	Withdrawal of ATD 2-30 days before RAI therapy	370 MBq

size precluded them from carrying out a multivariate logistic regression analysis. The level of precision of six of the cohort studies was deemed to be unclear due to the absence of confidence intervals. Overall, the cohort studies were regarded as having no or unclear implications for clinical practice due to small sample sizes, insignificant results and lack of conformity with other studies. Although the design of the case-control study (34) seemed appropriate, there were some uncertainties regarding the selection of the cases and controls due to lack of information. Furthermore, due to the small sample size, it would seem inappropriate to generalize the findings of this study to the rest of the population. A summary of this quality assessment can be seen in Table 6.

Domain 1	Domain 2	Domain 3	Domain 4	Domain 5	Overall
	Domain 1	Domain 1 Domain 2 A Company Domain 2 A Compa	Domain 1Domain 2Domain 3Image: Domain 2Image: Domain 3Image: D	Domain 1Domain 2Domain 3Domain 4Image: Problem Stress	Domain 1Domain 2Domain 3Domain 4Domain 5Image: Image: Imag

TABLE 4 Cochrane risk-of-bias tool for randomized trials (RoB 2).

Red indicates high concerns, yellow indicates some concerns and green indicates low concerns. Domain 1: Risk of bias arising from the randomization process. Domain 2: Risk of bias due to deviations from the intended interventions (effect of assignment to intervention). Domain 2: Risk of bias due to deviations from the intended interventions (effect of adhering to intervention). Domain 3: Risk of bias due to missing outcome data. Domain 4: Risk of bias in measurement of the outcome. Domain 5: Risk of bias in selection of the reported result.

Hyperthyroidism

While carbimazole reduced treatment success (defined as euthyroidism or hypothyroidism) in hyperthyroid patients overall, Walter et al. (36, 37) found that the impact was more pronounced in patients with Graves' disease than in patients with toxic nodular hyperthyroidism. Körber et al. (31) found that there was a significant reduction in treatment success between patients with toxic nodular goitre who took antithyroid drugs during and at least 14 days after RAI administration (discontinued one week before study endpoint measurements) and those who discontinued at least 14 days prior to RAI administration, but observed a nonsignificant reduction in patients with Graves' disease. Karyampudi et al. (35) found no significant effects of carbimazole on cure rates. However, they report that in patients who were pre-treated with carbimazole, those who took it for a shorter period were more likely to yield treatment failure (persistent hyperthyroidism) (35). Eschmann et al. (30) found that significantly fewer patients achieved treatment success (euthyroidism or hypothyroidism) if they continued to take antithyroid drugs (carbimazole, methimazole or propylthiouracil) compared to the group who discontinued these drugs 3-7 days before RAI.

Two studies considered the effect of 'block and replace' therapy. Bonnema et al. (28) found that a significant proportion of patients who continued 'block and replace therapy' during RAI administration were not cured in comparison to the control. This effect was observed in patients with toxic nodular hyperthyroidism but not in patients with Graves' disease. Counter to this, Andrade et al. (26) found no significant effects of methimazole pre-treatment on treatment outcomes and attribute this to the withdrawal of methimazole 4 days before RAI administration in conjunction with the high RAI dose use. Similarly, two studies found no significant differences in outcomes when patients continued to take methimazole during RAI administration (27, 29). Zantut-



TABLE 5 Critical Appraisal Skills Programme Cohort Study checklist.

Red indicates high risk of bias, yellow indicates unclear risk of bias and green indicates low risk of bias. Questions in checklist are: 1. Did the study address a clearly focused research question? 2. Was the cohort recruited in an acceptable way? 3. Was the exposure accurately measured to minimize bias? 4. Was the outcome accurately measured to minimize bias? 5. Have the authors identified all important confounding factors? 6. Have they taken account of the confounding factors in the design and/or analysis? 7. Was the follow up of subjects complete enough? 8. Was the follow up of subjects long enough? 9. What are the results of this study? 10. How precise are the results? 11. Do you believe the results? 12. Can the results be applied to the local population? 13. Do the results of this study fit with other available evidence? 14. What are the implications of this study for practice?

Authors	1	2	3	4	5	6	7	8	9	10	11	12
Oszukowska et al, 2010 (34)												
Red indicates high risk of bias, yellow indicates unclear risk of bias and green indicates low risk of bias. Questions in checklist are: 1. Did the study address a clearly focused research question? 2. Did the authors use an appropriate method to answer their question? 3. Were the cases recruited in an acceptable way? 4. Were the controls selected in an acceptable way? 5. Was the exposure accurately measured to minimize bias? 6. Aside from the experimental intervention, were the groups treated equally? 7. Have the authors taken account of the potential confounding factors in the design and/or in their analysis? 8. How large was the treatment effect? 9. How precise was the estimate of the treatment effect? 10. Do you believe the results? 11. Can the results be applied to the local population? 12. Do the results of this study fit with other available evidence?												

TABLE 6 Critical Appraisal Skills Programme Case-Control Study checklist.

Wittman et al. (33) found no significant relationship between the use of methimazole or propylthiouracil but did find that overall, antithyroid drug withdrawal 2-30 days before RAI administration was associated with treatment success in comparison to continuation. Santos et al. (32) reported propylthiouracil being more associated with treatment failure than methimazole.

In their case-control study, Oszukowska et al. (34) found that RAI administration was significantly less effective in patients who were pre-treated with thiamazole. The effect of prednisone was investigated in patients who had Graves' orbitopathy in the same study and it was found that patients who had taken prednisone before RAI administration achieved a higher cure rate than those in the control group, who did not have Graves' orbitopathy and were given RAI only (34). Although Oszukowska et al. (34) had no significant findings regarding lithium carbonate and RAI treatment outcomes, Płazińska et al. (41) found that patients who received lithium carbonate 6 days prior to and 3 days after RAI administration were more likely to achieve euthyroidism than those who did not receive lithium carbonate pre-treatment. However, these findings were only significant in the first year following RAI administration (41).

Out of the three studies analyzing the effects of lithium on RAI outcomes (38–40), two studies (38, 39) reported no significant effects on cure rate (defined as stable euthyroidism (38) or permanent hypothyroidism (39)), though Bogazzi et al. (39) note that hyperthyroidism was controlled faster in the two groups who either received lithium five days before RAI administration (for 19 days) or on the day of RAI administration (for six days) compared to the group did not receive lithium. Bogazzi et al. (40) defined cure as permanent hypothyroidism or stable euthyroidism. They (40) found cure rates were higher in the group who had received lithium five days before and seven days after RAI administration than in the group who did not receive lithium (40).

Thyroid cancer

Wen et al. (25) found that pre-treatment with glycididazole sodium increases complete response rate in patients with

differentiated thyroid cancer but has no significant effect on effective response rate. They also found Tg concentrations (unstimulated) were significantly lower in patients who had taken glycididazole sodium than those who had not at 12 weeks, although this difference was not observed at 24 weeks (25), suggesting this could be a transient effect. Tg was used as a surrogate marker in this study, and long-term outcomes including recurrence were not considered. The effects of other background medications were not considered in thyroid cancer patients.

Meta-analysis

Out of all the drugs assessed in these studies only methimazole and carbimazole (in hyperthyroidism) were investigated in multiple studies to consider meta-analysis (27, 32, 34–36). Results for other medications, including lithium, were too few to perform meta-analysis. No drugs were appropriate for meta-analysis in thyroid cancer due to the low number of studies. The I² statistic was 51% for the 5 studies defined for this analysis (Figure 2), above what was defined in the original PROSPERO database registration (<50%). Therefore, a subset analysis was also performed dividing the studies into randomized-control trials and non-randomized studies (Figure 3).

The subset analysis dividing randomized and nonrandomized studies (Figure 3) showed an I^2 of 0% for the RCTs and 44% for the non-randomized studies, indicating the heterogeneity is between these two groups and in the nonrandomized studies. However, as there were only two RCTs, additional clinical studies will be needed to improve meaningful conclusions from these comparisons.

The overall analysis (Figure 2) indicates there was moderate heterogeneity between the studies when all analyzed together $(I^2 = 51\%, \tau^2 = 0.0199, p = 0.08)$. The random effects model did show favorable treatment for the patients who were not on the drug carbimazole or methimazole (RR = 0.81, p = 0.02), supporting the findings of the qualitative systematic review. The prediction interval did however span the RR of 1, which is consistent with the study heterogeneity findings. These findings of our meta-analysis demonstrate that patients with



hyperthyroidism undergoing RAI therapy have worse cure rates if they are on antithyroid drugs such as carbimazole or methimazole.

Discussion

Hyperthyroidism

Of the 17 studies evaluated in this systematic review, 12 investigated the effect of antithyroid drugs (carbimazole, methimazole, thiamazole and propylthiouracil) on RAI therapy outcomes in hyperthyroid patients. This finding in itself demonstrates that the literature disproportionately represents thyroid related medication only, in terms of impact on RAI therapy. Our systematic review findings are largely consistent with those by Walter et al. (16) that antithyroid drugs have a negative impact on hyperthyroid patients' post-RAI therapy outcomes, seen as a reduction in success rate of RAI treatment.

Results from the five studies (30, 31, 35–37) involving carbimazole imply that the drug may be having negative effects on the success of RAI treatment in hyperthyroid

patients, but the effect on toxic nodular goitre patients versus Graves' disease patients seems to be inconsistent. It is interesting to note however, that univariate analysis by Karyampudi et al. (35) demonstrated that patients who took carbimazole for a shorter of period of time prior to RAI were more likely to remain hyperthyroid, highlighting a further area of research in this area.

Prednisone is a commonly prescribed corticosteroid with high glucocorticoid activity. Prednisone correlated with an increase in RAI treatment success, however it was only studied in one paper (34) hence no robust conclusions can be made. No significant effects of lithium carbonate were found in our review.

Studies of the effect of lithium were limited hence it would not be appropriate to form conclusions regarding this drug. However, lithium is a commonly prescribed drug in thyroid disease therefore, necessitating further information about its actions.

The meta-analysis in this study looked at cure rate, defined as euthyroidism or hypothyroidism, after radioactive iodine in patients who were taking carbimazole/methimazole versus control, which was limited to five studies. The antithyroid medication studies were the only studies that were numerate enough to perform a quantitative analysis. The I² value was 51%, demonstrating moderate heterogeneity to the studies analyzed.



Random effects meta-analysis of carbimazole/methimazole studies divided into randomized control trials (RCTs) and non-randomized studies that considered cure after radioactive iodine.

The meta-analysis demonstrates an improved rate of cure when patients are not taking antithyroid drugs, which is in keeping with the qualitative systematic review findings.

Papers were heavily focused on thyroid-related medications, which demonstrates the paucity of data on a patients' background medications and how these might affect RAI function.

Thyroid cancer

Enhanced understanding of the factors which impact thyroid cancer treatment success is required to address the ~45,000 lives lost worldwide to thyroid cancer per annum, which is estimated to rise to 74,733 by 2040 (42). In a screen of FDA-approved drugs, we recently demonstrated that common medications such as digoxin and pioglitazone gave negative values for the surrogate marker indicating reduced intracellular iodide, whereas clotrimazole and mifepristone gave positive values for the marker denoting increased intracellular iodide (21). These findings further underscore the need to investigate whether common medications taken by patients given RAI therapy impact on patient prognosis.

In the systematic review there was only one study specific to thyroid cancer (25), in which the effect of glycididazole sodium was explored. Glycididazole sodium is used as a radiosensitizing agent for radiotherapy in hypoxic tumors, but has not been extensively investigated in radioactive iodine therapy. Given that Wen et al. (25) reported increased complete response rates with glycididazole sodium, we suggest further trials should be performed to gain clarity on the effect the drug in thyroid cancer.

Limitations

One major drawback of this review is the quality of the studies evaluated. A majority of the RCTs were judged to be of high concern for risk of bias and all of the cohort studies were found to have either no or unclear implications for practice. This stems from the rather small sample sizes. In addition to this, only 17 studies were eligible for review, with only one pertaining to thyroid cancer patients. While it appears the effects of some drugs are clear, this may not be a true reflection of outcomes due to these drawbacks. We excluded non-English language studies which limited the studies we reviewed. Another limitation is that although we were able to assess results of each study, the outcome measurements differed between them.

The meta-analysis in this study was limited by the low number of studies included, and also by the study heterogeneity. Only the carbimazole/methimazole studies had enough studies with comparable outcomes (cure post-radioiodine treatment) to encourage meta-analysis. On registration of the systematic review in the PROSPERO database, performing a meta-analysis was limited to over five studies and a I² heterogeneity value of < 50%. An I^2 value of 51% was discovered in this review, but the meta-analysis has been included nonetheless.

Conclusions

Antithyroid drugs including carbimazole, methimazole, thiamazole and propylthiouracil have a negative impact on RAI outcomes in patients with hyperthyroidism. It seems that lithium, lithium carbonate and prednisone may have a positive impact on RAI outcomes in patients with hyperthyroidism, albeit this remains an area where further work is needed. In thyroid cancer patients, the effects of glycididazole sodium remain unclear. Our systematic review strengthens previous work, however this field remains under researched especially for medications unrelated to thyroid disease, with very few papers on non-thyroid medications published. Larger randomized-control trials with more uniform standards (e.g. definitions and measurements of thyroid status, length of follow up periods, outcome measurements) and larger scale observational studies investigating drugs commonly taken by thyroid cancer and hyperthyroid patients are urgently needed to inform clinical practice.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Author contributions

Authors contributed to the systematic review as reported: Study design conception, HN and JM, data collection and analysis, RZ, JL, and HN, manuscript writing, RZ, MR, HN, and CM, manuscript editing, RZ, JL, JM, MR, KBr, NS, KBo, CM, and HN, supervision, HN and CM. All authors contributed to the article and approved the submitted version.

Funding

Sir Arthur Thomson Charitable Trust Vacation Studentship (internal award from the University of Birmingham).

Acknowledgments

Evidence search: Do commonly used drugs diminish the efficacy of radioiodine treatment in hyperthyroidism and thyroid cancer? Jennifer Manders. (18th August, 2021). BIRMINGHAM, UK: University Hospitals Birmingham (UHB) Library and Knowledge Service.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. National Health Service. Overactive thyroid (hyperthyroidism)- treatment-NHS (2019). Available at: https://www.nhs.uk/conditions/overactive-thyroidhyperthyroidism/treatment/.

2. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. *Nature* (1996) 379(6564):458-60. doi: 10.1038/379458a0

3. Knostman KA, McCubrey JA, Morrison CD, Zhang Z, Capen CC, Jhiang SM. PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. *BMC Cancer* (2007) 7(1):137. doi: 10.1186/1471-2407-7-137

4. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. *J Clin Endocrinol Metab* (2007) 92(7):2840–3. doi: 10.1210/jc.2006-2707

5. Arriagada AA, Albornoz E, Opazo MC, Becerra A, Vidal G, Fardella C, et al. Excess iodide induces an acute inhibition of the Sodium/Iodide symporter in thyroid Male rat cells by increasing reactive oxygen species. *Endocrinology* (2015) 156(4):1540–51. doi: 10.1210/en.2014-1371

 Passon N, Puppin C, Lavarone E, Bregant E, Franzoni A, Hershman JM, et al. Cyclic AMP-response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells. *Thyroid* (2012) 22(5):487– 93. doi: 10.1089/thy.2011.0360

7. Ravera S, Reyna-Neyra A, Ferrandino G, Amzel LM, Carrasco N. The Sodium/Iodide symporter (NIS): Molecular physiology and preclinical and clinical applications. *Annu Rev Physiol* (2017) 79(1):261–89. doi: 10.1146/ annurev-physiol-022516-034125

8. Zhang Z, Liu D, Murugan AK, Liu Z, Xing M. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. *Endocr Relat Cancer* (2014) 21(2):161–73. doi: 10.1530/ERC-13-0399

9. Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated genomic characterization of papillary thyroid carcinoma. *Cell* (2014) 159(3):676–90. doi: 10.1016/j.cell.2014.09.050

10. Riesco-Eizaguirre G, Wert-Lamas L, Perales-Patón J, Sastre-Perona A, Fernández LP, Santisteban P. The miR-146b-3p/PAX8/NIS regulatory circuit modulates the differentiation phenotype and function of thyroid cells during carcinogenesis. *Cancer Res* (2015) 75(19):4119–30. doi: 10.1158/0008-5472.CAN-14-3547

11. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. *N Engl J Med* (2013) 368(7):623–32. doi: 10.1056/NEJMoa1209288

12. Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory *BRAF* V600E-mutant metastatic papillary thyroid cancer with dabrafenib. *Clin Cancer Res* (2015) 21(5):1028–35. doi: 10.1158/1078-0432.CCR-14-2915

13. Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, et al. Vemurafenib redifferentiation of *BRAF* mutant, RAI-refractory thyroid cancers. *J Clin Endocrinol Metab* (2019) 104(5):1417–28. doi: 10.1210/jc.2018-01478

14. Tchekmedyian V, Dunn L, Sherman E, Baxi SS, Grewal RK, Larson SM, et al. Enhancing radioiodine incorporation in *BRAF* -mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: Results of a pilot clinical trial. *Thyroid* (2022) 32(3):273–82. doi: 10.1089/thy.2021.0565

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fendo.2022.1061555/full#supplementary-material

15. Lubin DJ, Tsetse C, Khorasani MS, Allahyari M, McGrath M. Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience. *World J Nucl Med* (2021) 20(03):253–9. doi: 10.4103/wjnm.WJNM_104_20

16. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. *BMJ* (2007) 334(7592):514. doi: 10.1136/bmj.39114.670150.BE

17. Villanger GD, Drover SSM, Nethery RC, Thomsen C, Sakhi AK, Øvergaard KR, et al. Associations between urine phthalate metabolites and thyroid function in pregnant women and the influence of iodine status. *Environ Int* (2020) 137:105509. doi: 10.1016/j.envint.2020.105509

18. Greer MA, Goodman G, Pleus RC, Greer SE. Health effects assessment for environmental perchlorate contamination: the dose response for inhibition of thyroidal radioiodine uptake in humans. *Environ Health Perspect* (2002) 110 (9):927–37. doi: 10.1289/ehp.02110927

19. Braverman LE. Clinical studies of exposure to perchlorate in the united states. *Thyroid* (2007) 17(9):819-22. doi: 10.1089/thy.2007.0105

20. BMJ, Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* (2021) 372:n71. doi: 10.1136/bmj.n71

21. Read ML, Brookes K, Thornton CEM, Fletcher A, Nieto HR, Alshahrani M, et al. Targeting non-canonical pathways as a strategy to modulate the sodium iodide symporter. *Cell Chem Biol* (2022) 29(3):502-16. doi: 10.1016/j.chembiol.2021.07.016

22. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* (2019) 366: 14898. doi: 10.1136/bmj.14898

23. Critical Appraisal Skills Programme. United Kingdom. CASP Cohort Study Checklist. (2022) [online] Available at: https://casp-uk.net/casp-tools-checklists/.

24. Critical Appraisal Skills Programme. United Kingdom. CASP Case Control Study Checklist. (2022) [online] Available at: https://casp-uk.net/casp-tools-checklists/.

25. Wen Q, Ma Q, Bai L, Wang T, Han Y, Zhang H. Glycididazole sodium combined with radioiodine therapy for patients with differentiated thyroid carcinoma (DTC). *Int J Clin Exp Med* (2015) 8(8):14095–14099.

26. Andrade VNA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in graves' hyperthyroidism: One-year follow-up of a prospective, randomized study. *J Clin Endocrinol Metab* (2001) 86 (8):3488–3493. doi: 10.1210/jcem.86.8.7707

27. Bonnema SJ, Bennedbæk FN, Veje A, Marving J, Hegedüs L. Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: An evaluation by a randomized trial. *J Clin Endocrinol Metab* (2006) 91(8):2946–51. doi: 10.1210/jc.2006-0226

28. Bonnema SJ, Grupe P, Boel-Jørgensen H, Brix TH, Hegedüs L. A randomized trial evaluating a block-replacement regimen during radioiodine therapy: BLOCK-REPLACEMENT REGIMEN DURING RADIOIODINE THERAPY. *Eur J Clin Invest* (2011) 41(7):693-702. doi: 10.1111/j.1365-2362.2010.02452.x

29. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for graves' hyperthyroidism:

A randomized clinical trial. Thyroid (2002) 12(2):135-9. doi: 10.1089/ 105072502753522365

30. Eschmann S, Thelen M, Dittmann H, Bares R. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of graves' disease: Results of a prospective study. *Exp Clin Endocrinol Diabetes* (2006) 114 (05):222–6. doi: 10.1055/s-2006-924238

31. Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in graves' disease and toxic nodular goitre? *Eur J Nucl Med* (2001) 28(9):1360–4. doi: 10.1007/s002590100565

32. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with graves' disease. *Thyroid* (2004) 14(7):525–30. doi: 10.1089/1050725041517093

33. Zantut-Wittmann DE, Ramos CD, Santos AO, Lima MMO, Panzan AD, Facuri FO, et al. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [1311]iodide therapy in graves' disease. *Nucl Med Commun* (2005) 26(11):957–63. doi: 10.1097/01.mnn.0000183795.59097.42

34. Oszukowska L, Knapska-Kucharska M, Makarewicz J, Lewiński A. The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment (1311) in hyperthyroid patients. *Endokrynol Pol* (2010) 61(1):56–61.

35. Karyampudi A, Hamide A, Halanaik D, Sahoo JP, Kamalanathan S. Radioiodine therapy in patients with graves' disease and the effects of prior carbimazole therapy. *Indian J Endocrinol Metab* (2014) 18(5):7. doi: 10.4103/2230-8210.139234

36. Walter MA, Christ-Crain M, Schindler C, Müller-Brand J, Müller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. *Eur J Nucl Med Mol Imaging* (2006) 33(6):730-7. doi: 10.1007/s00259-006-0092-8

37. Walter MA, Schindler C, Christ-Crain M, Müller-Brand J, Müller B. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models. *Eur J Clin Invest* (2009) 39(1):51–7. doi: 10.1111/j.1365-2362.2008.02061.x

38. Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. *Thyroid* (2002) 12(5):399–405. doi: 10.1089/105072502760043486

39. Bogazzi F, Bartalena L, Campomori A, Brogioni S, Traino C, De Martino F, et al. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with graves' disease. *J Clin Endocrinol Metab* (2002) 87(10):4490–5. doi: 10.1210/jc.2002-020580

40. Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, et al. Impact of lithium on efficacy of radioactive iodine therapy for graves' disease: A cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. *J Clin Endocrinol Metab* (2010) 95(1):201–8. doi: 10.1210/jc.2009-1655

41. Płazińska MT, Królicki L, Bąk M. Lithium carbonate pre-treatment in 131-I therapy of hyperthyroidism. *Nucl Med Rev* (2011) 14(1):6. doi: 10.5603/NMR.2011.0002

42. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* (2019) 144(8):1941–53. doi: 10.1002/ijc.31937